The encouraging results of the phase 3 ORIENT-11 trial, which included 397 patients with previously untreated, locally advanced metastatic non-squamous NSCLC without sensitizing EGFR or ALK aberrations, were published in the Journal of Thoracic Oncology.
PATIENT EDUCATION
OBESITY/WEIGHT MANAGEMENT
EXERCISE/TRAINING
LEGAL MATTERS
GUIDELINES/RECOMMENDATIONS